TICKERNERD
Menu
HCWBHCWBHealthcare · Biotechnology

HCWB Stock Forecast: HCW Biologics Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$1.17

The 1 Wall Street analysts covering HCW Biologics Inc. hold a median 12-month price target of $48 — +4002.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 54 of 100 as at 14 Oct 2026 — in the upper half.

Market cap
$2.6M
Ticker Nerd rank
54 / 100
Median analyst target
$48
Analysts covering
1
Revenue$136K+1969.7% y/y
Operating income−$3.2M
Net income−$5.2M
Free cash flow−$4.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

HCWB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores HCW Biologics Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
54 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
98
Growth
81
Accruals
79
Issuance
51
Quality
44
Volatility
42
Revisions
35
Momentum
29
Value
26

Size (98): Smaller than most of the companies we track.

Value (26): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

HCWB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HCWB, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $48Median $48High $48

The green dot is the last close — the median target sits +4002.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
28 May 2026Maxim GroupMaintainsBuy—
28 May 2026Maxim GroupMaintainsBuy$2.00 → $5.00
29 May 2025Maxim GroupMaintainsBuy—
1 June 2023EF HuttonAssumesBuy$9.00
19 Apr 2023EF HuttonReiteratesBuy—
30 Mar 2023EF HuttonReiteratesBuy—
23 Mar 2023EF HuttonReiteratesBuy—
8 Nov 2022JonesTradingInitiatesBuy—
24 Mar 2022Maxim GroupInitiatesBuy—
19 Nov 2021EF HuttonInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HCWB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

HCWB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

HCW Biologics Inc. (HCWB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.0×

Cheaper than 76% of US stocks

Price / sales
0.4×

Cheaper than 81% of US stocks

Price / book
0.3×

Cheaper than 87% of US stocks

EV / EBITDA
−1.4×

Cheaper than 71% of US stocks

Growth & margins
Revenue growth (YoY)
1969.7%

Higher than 99% of US stocks

Earnings growth (YoY)
1969.7%

Higher than 98% of US stocks

Gross margin
−69.3%

Higher than 2% of US stocks

Operating margin
−2335.6%

Higher than 4% of US stocks

Net margin
−83.0%

Higher than 7% of US stocks

Returns & dividend
Return on equity
−151.4%

Higher than 9% of US stocks

Return on assets
−13.9%

Higher than 23% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

HCW Biologics Inc. (HCWB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • HCW Biologics Inc. has a market value of $2.6M and an enterprise value of $8.0M.

  • Revenue in the twelve months to 30 June 2026: $6.7M. The latest quarter grew 1969.7% year on year.

  • Net income over the same four quarters: −$5.6M, a −83.0% net margin.

  • Diluted earnings per share, trailing twelve months: $−28.43.

  • Free cash flow in the twelve months to 30 June 2026: −$12.1M.

  • Shares outstanding: 1.6M.

  • Trailing P/E: −0.0×; forward P/E: −2.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • HCW Biologics Inc. employs 35 people — $192K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Oct 2026

Data provided by Twelve Data

Peers

HCWB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
HCWBHCW Biologics Inc.$2.6M
54
VIVSVivoSim Labs, Inc.$2.7M
34
KAPAKairos Pharma Ltd.$2.5M
37
SLXNSilexion Therapeutics Corp.$2.5M
56
DCOYDecoy Therapeutics, Inc.$2.8M
19
MBIOMustang Bio, Inc.$2.8M
14
GOVXGeoVax Labs, Inc.$2.4M
34

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own HCW Biologics Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HCWB news & analysis

HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors

GlobeNewsWire · 9 Oct 2026positive

HCW Biologics said a recent Type B meeting with the FDA provided clear guidance on next steps toward preparing an IND application for a first-in-human clinical study of its lead T-cell engager in solid tumors.

Why it matters — The update concerns regulatory planning for HCWB’s lead candidate and its proposed clinical study in cancer.

HCW Biologics Announces Pricing of $1.5 Million Private Placement

GlobeNewsWire · 24 Sept 2026neutral

HCW Biologics announced the pricing of a $1.5 million private placement with an existing stockholder. The clinical-stage biopharmaceutical company is developing fusion immunotherapeutics for autoimmune diseases, cancer, and senescence-associated dysplasia.

Why it matters — HCWB watchers would care because the private placement provides new funding for the company's development programs from an existing investor.

HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells

GlobeNewsWire · 8 Sept 2026positive

HCW Biologics entered an exclusive distribution agreement with Akron Biotech to commercialize HCW11-006, a second-generation multi-cytokine-based reagent used to support production of highly functional human CAR-T cells. The agreement includes pre-payment commitments for product sales and distribution.

Why it matters — HCWB watchers would care because the exclusive distribution agreement with pre-payment commitments provides a commercialization pathway for HCW11-006 in the CAR-T cell production space.

HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment

GlobeNewsWire · 2 Sept 2026positive

HCW Biologics announced that the USPTO issued a Notice of Allowance for patent claims covering the use of its lead clinical-stage immunotherapeutic HCW9302 as a treatment for alopecia areata. The ongoing Phase 1 dose-escalating study of HCW9302 as a monotherapy remains on track for completion in Q4 2026, with no dose-limiting toxicities and encouraging preliminary results from the first two dose cohorts.

Why it matters — The patent allowance strengthens HCW Biologics' U.S. intellectual property protection for HCW9302, while the encouraging early trial data and progress toward completing the Phase 1 study support the advancement of its lead candidate in treating alopecia areata.

HCW Biologics' TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells

GlobeNewsWire · 25 Aug 2026positive

HCW Biologics, with collaborators at leading research institutions, identified a TGF-β trap and IL-15 fusion as a novel moiety with potential applications against diseased cells and viral infections. Human studies showed the moiety alone promotes expansion of progenitor CD8+ T cells and NK cells, and the company has incorporated it into its second-generation fusion immunotherapeutics built on its TRBC drug development platform.

Why it matters — This development highlights a potentially enhanced component built into HCW Biologics' second-generation fusion immunotherapeutics that could broaden their therapeutic applicability across cancer, autoimmune disease, and viral infections.

FAQ

Frequently asked questions about HCWB stock

What is the HCWB stock price forecast for 2026-2027?

The 1 Wall Street analysts covering HCW Biologics Inc. have a median 12-month price target of $48, with estimates ranging from $48 to $48. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HCWB stock a buy right now?

Of the 1 analysts covering HCW Biologics Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks HCW Biologics Inc. 54 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HCWB?

As at 14 Oct 2026, HCW Biologics Inc. ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

Will HCWB stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +4002.6% from the last close, and Ticker Nerd's factor model ranks HCW Biologics Inc. 54 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HCWB stock forecast for 2030?

No analyst covering HCW Biologics Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HCWB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $48 to $48 over the next 12 months.

What does HCW Biologics Inc. do?

HCW Biologics Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for diseases driven by chronic, low-grade inflammation.

What is the latest news on HCWB?

The most recent item we track (GlobeNewsWire, 9 Oct 2026): "HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors". HCW Biologics said a recent Type B meeting with the FDA provided clear guidance on next steps toward preparing an IND application for a first-in-human clinical study of its lead T-cell engager in solid tumors.

Company

About HCW Biologics Inc.

HCW Biologics Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for diseases driven by chronic, low-grade inflammation. The company’s current work centers on fusion protein-based drug candidates designed to address autoimmune disorders, cancer, and age-related inflammatory conditions. Its research programs use proprietary platforms to create biologic molecules intended to modulate immune responses and target pathways linked to inflammaging and senescence. HCW Biologics operates in the biotechnology sector, with a business model built around discovery, preclinical development, and early-stage clinical testing of its therapeutic pipeline. Based in Miramar, Florida and founded in 2018, HCW Biologics aims to advance treatments that may have applications across oncology, immunology, and other inflammatory disease areas.

CEO Dr. Hing C. Wong Ph.D. · 35 employees · United States · https://www.hcwbiologics.com